
Semax
Potential Benefits
- Approved in Russia for stroke, cognitive disorders, and neurodegenerative conditions
- Research suggests neuroprotective properties through BDNF upregulation
- Studies indicate potential improvements in attention, memory, and mental clarity
- May support recovery from brain injuries based on clinical data from Russian studies
- Preclinical research suggests anti-inflammatory effects in neural tissue
- Does not appear to cause significant sedation or stimulation
Recommended Starting Dose
200-600 mcg intranasally per day
Based on published research protocols. Not a prescription.
Dosing Protocol
Administered intranasally at 200-600 mcg per day, typically divided into 2-3 doses. A standard course in Russian clinical practice is 10-14 days, which may be repeated after a break. Higher doses (up to 1.2 mg/day) are used in some clinical settings for acute neurological conditions.
DOSING INFORMATION DISCLAIMER: Any dosing information, protocols, or ranges discussed on this site are drawn from published research studies and clinical literature. They are presented for educational reference only and must not be used as self-medication guidance.
Expected Timeline
Phase 1
Cognitive effects such as improved focus and mental clarity are often reported within the first 3-5 days. Neuroprotective benefits in clinical applications require sustained use.
Research Status
The regulatory status of peptides can change at any time. Verify current FDA classification and legal status in your jurisdiction before seeking medical consultation about this compound.
Potential Side Effects
- Nasal dryness or irritation
- Mild headache in some users
- Hair loss reported anecdotally at higher doses
- Potential irritability in sensitive individuals
- Limited Western clinical safety data
- Possible interactions with psychoactive medications
More in Cognitive

Selank
Selank
Selank is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is derived from the naturally occurring immunomodulatory peptide tuftsin with an added Pro-Gly-Pro sequence for stability. It is approved in Russia as an anxiolytic and nootropic nasal spray.

Dihexa
Dihexa
Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a synthetic peptide derived from angiotensin IV. Developed at Washington State University by Dr. Joseph Harding, it was found to be up to 10 million times more potent than BDNF at promoting hepatocyte growth factor (HGF) signaling. Research has focused on its potential to drive synaptogenesis and cognitive enhancement.

PE-22-28
PE-22-28 (Spadin analog)
PE-22-28 is a synthetic heptapeptide derived from spadin, which itself is a fragment of the sortilin propeptide. It acts as an antagonist of the TREK-1 potassium channel, a validated target for antidepressant activity. Research suggests it may have rapid-onset antidepressant-like effects in animal models, acting within days rather than weeks.
Medical Disclaimer
EDUCATIONAL CONTENT ONLY: The peptide information presented on this page is compiled from published scientific literature, peer-reviewed research, and publicly available clinical data. It is provided strictly for educational purposes and does not constitute medical advice, an endorsement of any specific peptide, or a recommendation for treatment. Many peptides discussed on this site have not received FDA approval for human therapeutic use. Some may be under active regulatory review or subject to restrictions on compounding under FDA Section 503A and 503B frameworks. The regulatory status of individual peptides can change at any time. Readers should verify the current legal status of any peptide in their jurisdiction before pursuing further information or consultation. If you are considering peptide therapy, seek guidance from a licensed physician or healthcare provider who specializes in peptide-based treatments and operates within applicable federal and state regulations.